Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses and prevents tumor growth in preclinical modelsEVX-04 is an off-the-shelf therapeutic cancer vaccine developed for acute myeloid leukemia (AML), a disease characterized by high mortality rates and massive unmet medical needThe off-the-shelf vaccine concept behind EVX-04 is broadly applicable with po ...